Clinical Trials Related to Pembrolizumab

Related studies linked through entity extraction aliases.

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE2/PHASE3

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Status: RECRUITING
Phase: PHASE3

A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)

Status: RECRUITING
Phase: PHASE1/PHASE2

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Status: RECRUITING
Phase: PHASE2

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Status: NOT_YET_RECRUITING
Phase: PHASE1

Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01

Status: RECRUITING
Phase: PHASE2

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Status: RECRUITING
Phase: PHASE1/PHASE2

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Status: RECRUITING
Phase: PHASE1/PHASE2

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Status: NOT_YET_RECRUITING
Phase: PHASE3

Amping up With PemJAK

Status: RECRUITING
Phase: PHASE2

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

Status: RECRUITING
Phase: PHASE2

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Status: RECRUITING
Phase: PHASE3

Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment

Status: RECRUITING
Phase: PHASE2

A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC

Status: RECRUITING
Phase: PHASE2

A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC

Status: RECRUITING
Phase: PHASE1/PHASE2

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Status: RECRUITING
Phase: PHASE2

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

Status: RECRUITING
Phase: PHASE1

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE1

KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

Status: RECRUITING
Phase: PHASE1/PHASE2

A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies

Status: RECRUITING
Phase: PHASE1